<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of novel isatinâ€&quot;nicotinohydrazide hybrids with potent activity against susceptible/resistant Mycobacterium" exact="tuberculosis" post="and bronchitis causingâ€&quot;bacteria Z. M. Elsayed et al. Journal"/>
 <result pre="Joining the global fight against Tuberculosis, the world's most deadly" exact="infectious disease," post="herein we present the design and synthesis of novel"/>
 <result pre="activity of the target hybrids was evaluated against drug-susceptible M." exact="tuberculosis" post="strain (ATCC 27294) where hybrids 5d, 5g and 5h"/>
 <result pre="Âµg/mL, also the activity was evaluated against Isoniazid/Streptomycin resistant M." exact="tuberculosis" post="(ATCC 35823) where compounds 5g and 5h showed excellent"/>
 <result pre="six bronchitis causing-bacteria. Most derivatives exhibited excellent antibacterial activity. K." exact="pneumonia" post="emerged as the most sensitive strain with MIC range:"/>
 <result pre="Rifampicin, Ethambutol, and Streptomycin have shown significant activity against Mycobacterium" exact="tuberculosis" post="however, the emergency of drug-resistant TB (DR-TB), especially multi-drug"/>
 <result pre="synthesised, and evaluated for their anti-tubercular activity against drug-susceptible M." exact="tuberculosis" post="strain (ATCC 27294) and Isoniazid/Streptomycin resistant M. tuberculosis (ATCC"/>
 <result pre="drug-susceptible M. tuberculosis strain (ATCC 27294) and Isoniazid/Streptomycin resistant M." exact="tuberculosis" post="(ATCC 35823), together with the antibacterial effect against bronchitis"/>
 <result pre="being critical enzymes in the metabolism and synthesis of M." exact="tuberculosis" post="cell wall30,31 to explore the possible mechanism of action"/>
 <result pre="synthesised hybrids were evaluated for their anti-tubercular action towards M." exact="tuberculosis" post="(ATCC 27294) using the Microplate Alamar Blue Assay (MABA)32."/>
 <result pre="MIC (Âµg/mL) for hybrids (5aâ€&quot;m, 9aâ€&quot;c, and 14) against M." exact="tuberculosis" post="(ATCC 27294) and Isoniazid/Streptomycin resistant M. tuberculosis (ATCC 35823),"/>
 <result pre="14) against M. tuberculosis (ATCC 27294) and Isoniazid/Streptomycin resistant M." exact="tuberculosis" post="(ATCC 35823), and LogP measurements for hybrids (5aâ€&quot;m, 9aâ€&quot;c,"/>
 <result pre="9aâ€&quot;c, and 14). Compound X or R2 R R1 M." exact="tuberculosis" post="(ATCC 27294) M. tuberculosis (ATCC 35823) LogP 5a H"/>
 <result pre="X or R2 R R1 M. tuberculosis (ATCC 27294) M." exact="tuberculosis" post="(ATCC 35823) LogP 5a H â€&quot;CH2CH2CH3 Â 3.9 125"/>
 <result pre="hybrids. 2.2.2. Anti-tubercular activity towards Isoniazid and Streptomycin resistant M." exact="tuberculosis" post="(ATCC 35823) The anti-tubercular activity against Isoniazid and Streptomycin"/>
 <result pre="35823) The anti-tubercular activity against Isoniazid and Streptomycin resistant M." exact="tuberculosis" post="(ATCC 35823) was evaluated using MABA32. Investigating the results"/>
 <result pre="5g and 5h with the best anti-tubercular effect against M." exact="tuberculosis" post="(ATCC 27294), showed excellent activity (MIC = 3.9â€‰Âµg/mL) resistant"/>
 <result pre="(ATCC 27294), showed excellent activity (MIC = 3.9â€‰Âµg/mL) resistant M." exact="tuberculosis" post="strain (ATCC 35823), with more than 32 fold increase"/>
 <result pre="43816), H. influenzae (ATCC 10211), M. catarrhalis (ATCC 25238), B." exact="pertussis" post="(ATCC 9340) and Gram-positive S. pneumoniae (ATCC 1659) using"/>
 <result pre="1659) K. pneumoniae (ATCC 43816) M. catarrhalis (ATCC 25238) B." exact="pertussis" post="(ATCC 9340) 5a 7.81 7.81 1.95 0.49 31.25 3.9"/>
 <result pre="the reference drug against H. influenzae, M. catarrhalis, and B." exact="pertussis" post="(MIC = 0.24â€&quot;3.9â€‰Âµg/mL, Azithromycin MIC = 3.9â€&quot;7.81â€‰Âµg/mL). Additionally, they"/>
 <result pre="(ATCC 15531), H. influenza, M. catarrhalis (ATCC 25238) and B." exact="pertussis" post="(ATCC 9340). Also, compound 5j was as potent as"/>
 <result pre="K. pneumoniae (ATCC 43816), M. catarrhalis (ATCC 25238), and B." exact="pertussis" post="(ATCC 9340). Furthermore, compounds 5f and 14 were two-fold"/>
 <result pre="MIC = 1.95â€‰Âµg/mL) than Azithromycin (MIC = 3.9â€‰Âµg/mL) against H." exact="influenza" post="(ATCC 10211) and B. pertussis (ATCC 9340) and equipotent"/>
 <result pre="(MIC = 3.9â€‰Âµg/mL) against H. influenza (ATCC 10211) and B." exact="pertussis" post="(ATCC 9340) and equipotent to Azithromycin against K. pneumoniae"/>
 <result pre="their possible molecular target. Two promising drug enzymes in M." exact="tuberculosis" post="were suggested as potential targets for the target compounds"/>
 <result pre="14 were designed and synthesised. The anti-mycobacterial activity towards M." exact="tuberculosis" post="(ATCC 27294), as well as towards the INH and"/>
 <result pre="as well as towards the INH and Streptomycin resistant M." exact="tuberculosis" post="(ATCC 35823), were evaluated for the seventeen newly synthesised"/>
 <result pre="all herein prepared hybrids (5aâ€&quot;m, 9aâ€&quot;c, and 14) against M." exact="tuberculosis" post="ATCC 27294 (Isoniazid-susceptible strain) and Mycobacterium tuberculosis ATCC 35823"/>
 <result pre="14) against M. tuberculosis ATCC 27294 (Isoniazid-susceptible strain) and Mycobacterium" exact="tuberculosis" post="ATCC 35823 (Isoniazid and Streptomycin resistant strain). The detailed"/>
 <result pre="K. pneumoniae ATCC 43816, M. catarrhalis ATCC 25238, and Bordetella" exact="pertussis" post="ATCC 9340, as well as S. pneumoniae ATCC 1659,"/>
 <result pre="WHO. Geneva, Switzerland: WHO; 2018. 3ConinxR, MathieuC, DebackerM, et al.First-line" exact="tuberculosis" post="therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet1999;353:969â€&quot;73.10459906 4LangbangA,"/>
 <result pre="3ConinxR, MathieuC, DebackerM, et al.First-line tuberculosis therapy and drug-resistant Mycobacterium" exact="tuberculosis" post="in prisons. Lancet1999;353:969â€&quot;73.10459906 4LangbangA, DekaN, RahmanH, KalitaD.A study on"/>
 <result pre="on bacterial pathogens causing secondary infections in patients suffering from" exact="tuberculosis" post="and their pattern of antibiotic sensitivity. Int J Curr"/>
 <result pre="multidrug-resistant tuberculosis. ERJ Open Res2017;3:00026. 8KunalS, ShahA.The concomitant occurrence of" exact="pulmonary tuberculosis" post="with bronchial anthracofibrosis. Indian J Tuberc2017;64:5â€&quot;9.28166918 9KidwaiM, JahanA, MishraNK.Isatins:"/>
 <result pre="tuberculosis. ERJ Open Res2017;3:00026. 8KunalS, ShahA.The concomitant occurrence of pulmonary" exact="tuberculosis" post="with bronchial anthracofibrosis. Indian J Tuberc2017;64:5â€&quot;9.28166918 9KidwaiM, JahanA, MishraNK.Isatins:"/>
 <result pre="series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7" exact="breast cancer" post="cells. Eur J Med Chem2018;155:782â€&quot;96.30047410 42MakarovV, LechartierB, ZhangM, et"/>
 <result pre="of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast" exact="cancer" post="cells. Eur J Med Chem2018;155:782â€&quot;96.30047410 42MakarovV, LechartierB, ZhangM, et"/>
 <result pre="42MakarovV, LechartierB, ZhangM, et al.Towards a new combination therapy for" exact="tuberculosis" post="with next generation benzothiazinones. EMBO Mol Med2014;6:372â€&quot;83.24500695 43SullivanTJ, TruglioJJ,"/>
</results>
